Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Viatris Inc (NQ: VTRS )

9.640 -0.050 (-0.52%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 22, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Viatris Inc

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
NASDAQ: VTRS Shareholder Notice Investigation over Potential Wrongdoing by Certain Directors of Viatris Inc.
San Diego, CA -- (SBWIRE) -- 09/22/2023 -- Certain directors of Viatris Inc.are under investigation concerning potential breaches of fiduciary duties. 
Via SBWire
'Stocks In Monopolistic Bull Market': Wall Street Analyst Contemplates A Bright Future For Next Phase
The analyst illustrated how the dominant force in stock market returns for 2023 has been the "Magnificent 7." 
Via Benzinga
Want to Collect $500 in Dividends Every Month? Invest $90,000 in These 3 Stocks
These stocks offer some mouth-watering payouts. 
Via The Motley Fool
3 Pharmaceutical Stocks That Are Too Cheap to Ignore
Viatris, GSK, and Organon are all trading at less than 7 times earnings. 
Via The Motley Fool
Viatris Stock: Bear vs. Bull
This is a case where both sides have compelling arguments. 
Via The Motley Fool
Better High-Yield Dividend Stock: Takeda Pharmaceutical vs. Viatris
Via The Motley Fool
Where Will Viatris Be in 5 Years?
Can this become a good growth business to invest in? 
Via The Motley Fool
2 Beaten-Down Dividend Stocks to Buy
These two stocks look like bargains right now for income investors. 
Via The Motley Fool
CVS Health Just Created a New Problem For Viatris. Here's What You Need to Know
CVS just fired a shot across Viatris' bow. 
Via The Motley Fool
VIATRIS ALERT: Bragar Eagel & Squire, P.C. is Investigating Viatris Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
Viatris Could Soon Make a Generic Ozempic, But Does That Make It a Buy?
There are a few complicating factors that mean the generic form of the drug might not be a slam dunk. 
Via The Motley Fool
If You'd Invested $25,000 in Viatris in 2020, This Is How Much You Would Have Today
Would you have been better off investing in the S&P 500? 
Via The Motley Fool
Topics Stocks
Exposures US Equities
Is Viatris Stock Good for Dividend Income?
If you keep your expectations in check, it could be a great pick. 
Via The Motley Fool
A Preview Of Viatris's Earnings
Via Benzinga
Viatris Stock: Bull vs. Bear
Viatris shares have declined in the double digits over the past few years. 
Via The Motley Fool
Daily Stock Analysis: Viatris
Viatris Inc’s most recent $0.12 quarterly dividend, paid June 16th to shareholders of record May 23rd, equates to $0.48 annually to throw a yield of 4.58%. 
Via Talk Markets
Better Pharma Buy: Viatris vs. Pfizer
Both stocks look cheap today. 
Via The Motley Fool
Viatris Q2 Earnings Beat Estimates, Multiple Sclerosis Therapy Accepted For FDA Review
Viatris Inc (NASDAQ: VTRS) reported Q2 FY23 sales of $3.91 billion, up 2% on a divestiture-adjusted operational basis, marginally higher the  
Via Benzinga
Elanco Animal Health, Sovos Brands, Veritiv, Graham And Other Big Stocks Moving Higher On Monday
U.S. stocks traded higher, with the Dow Jones gaining around 300 points on Monday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Want $1,500 in Annual Passive Income? Invest This Much in Viatris Stock Each Month for 5 Years
If you're patient and consistent, it won't be too hard to build up a revenue stream. 
Via The Motley Fool
1 Reason I Wouldn't Buy This High-Yielding Dividend Stock
Unless you're only in it for the dividend, you might be disappointed with this stock. 
Via The Motley Fool
A Look Into Healthcare Sector Value Stocks
Via Benzinga
Better High-Yield Dividend Stock: Altria or Viatris?
Which of these top income stocks is the better buy right now? 
Via The Motley Fool
VTRS DEADLINE TODAY: ROSEN, A TOP RANKED LAW FIRM, Encourages Viatris Inc. Investors with Losses to Secure Counsel Before Important July 14 Deadline in Securities Class Action - VTRS
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
3 Reasons to Buy Viatris Stock, and 1 Reason to Sell
This drugmaker could be a great stock to own over the coming years. 
Via The Motley Fool
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Viatris Inc. (VTRS)
From The Law Offices of Frank R. Cruz
Via Business Wire
3 Healthcare Stocks With Healthy Dividends
These pharmaceutical companies all combine relatively high dividends with safe payout ratios. 
Via The Motley Fool
VTRS DEADLINE: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Viatris Inc. Investors to Secure Counsel Before Important July 14 Deadline in Securities Class Action - VTRS
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
VIATRIS INC. (NASDAQ: VTRS) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Viatris Inc.
From Bernstein Liebhard LLP
Via GlobeNewswire
ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Viatris Inc. Investors to Secure Counsel Before Important July 14 Deadline in Securities Class Action - VTRS
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.